For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...
As evidence grows supporting the potential health benefits of obesity drugs like Novo Nordisk’s Wegovy and Eli Lilly & Co.’s Zepbound, so too — frustratingly — do the barriers to accessing them. The ...
A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager ...
Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect ...
As evidence grows supporting the potential health benefits of obesity drugs like Novo Nordisk’s Wegovy and Eli Lilly & Co.’s Zepbound, so too — frustratingly — do the barriers to accessing them. The ...
(CNN) — A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit ...
Eli Lilly cuts cash prices for Zepbound weight-loss vials on LillyDirect, offering doses from $299 to $449 as demand for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback